BIO CEO & Investor Conference
Despite a record number of large deals across the pharmaceutical and biotechnology landscape, market indicators are pointing toward a noticeable shift in the appetite for global deal-making across the industry. As the pool of high-valued assets becomes smaller, will signs point to a drastic increase in smaller deals for larger pharma companies looking to solidify their balance sheets across core therapeutic areas? How does a strong public market with a well-capitalized pool of young biotech targets that don’t need to be forced into an early buyout impact this hypothetical M&A shift? This session will feature experienced voices explaining the public perspective for a potentially active year within pharma and biotech deal-making.
Moderator:
Panel speakers:
Disclaimer
Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.